Directory
The companies behind the science.
Listed and private companies with real longevity exposure, ASX or SGX listed or headquartered in Singapore or Australia. Switch category with the tabs, choose a market on the right, then narrow by exchange or status.
SGX Catalist:MIJ
Alliance Healthcare Group Limited
Qualifies on both limbs: listed on SGX Catalist under MIJ and headquartered in Singapore (25 Bukit Batok Crescent). Alliance is an investment holding company running an integrated Singapore healthcare network: GP clinic services (My Family Clinic), specialist care, managed healthcare solutions sold to corporates and insurers, pharmaceutical services, radiology, home care (JagaMe) and a digital health app (HeyAlly). It states access to more than 2,000 in-house and partner medical facilities in Singapore, and had 395 employees with a July-June fiscal year. The longevity-relevant activity is preventive and occupational health screening delivered at scale through corporate health plans and the GP network, plus imaging and teleconsultation that route screening findings into follow-up care. It is a care-delivery and screening distribution business, not a developer of ageing-biology therapeutics or biomarker tests, so exposure is to the preventive-screening and primary-care layer rather than to any geroscience intervention.
ASX:ATH
Alterity Therapeutics Limited
Clinical-stage biotech developing disease-modifying drugs for neurodegenerative disease. Lead candidate ATH434 is an oral small molecule designed to reduce excess iron accumulation in the brain and inhibit aggregation of alpha-synuclein, the protein implicated in Multiple System Atrophy and related synucleinopathies. It targets the underlying biology of age-related neurodegeneration rather than symptoms, which is the longevity-relevant part. ATH434 has completed a randomised placebo-controlled Phase 2 trial in MSA plus an open-label Phase 2 in advanced MSA, and the company is working toward a pivotal Phase 3. It is a single-asset, pre-revenue developer, so exposure is binary on that program.
Private
AMILI
Microbiome science company running a multi-ethnic Asian gut microbiome biobank and reference database, which it uses to interpret consumer and clinician-ordered stool tests. Commercial output is diagnostic rather than therapeutic: a gut microbiome test kit and an enhanced version, four targeted probiotic formulations (immune-metabolic, complete, cognitive, digestive), microbiome restoration therapy, and AMILI Optimise Plus, a metabolic health programme that pairs microbiome profiling with continuous glucose monitoring and nutritionist input. Distribution runs through a partner clinic network. Longevity relevance is indirect: it sits in the metabolic-health and personalised-nutrition layer, measuring and modifying a biomarker set (gut composition, glycaemic response) associated with cardiometabolic risk, not intervening in ageing biology directly. Efficacy claims for microbiome-guided nutrition remain contested in the literature; the company's own database size claims are self-reported and not independently verified here.
Private
Atisama Therapeutics (formerly RAGE Biotech / Rage Bio Pty Ltd)
Develops inhaled splice-switching oligonucleotide (RNA) drugs aimed at the RAGE receptor, the receptor for advanced glycation end-products. Lead candidate RB042 inhibits full-length RAGE while increasing the soluble decoy form esRAGE in the lung, with the goal of damping chronic airway inflammation. It is in a Phase 1 trial (NCT07285122) in healthy volunteers and healthy smokers, targeting COPD; the stated pipeline also covers alpha-1 antitrypsin deficiency, neutrophilic asthma and idiopathic pulmonary fibrosis. The longevity relevance is mechanistic rather than claimed by the company: RAGE-AGE signalling sits at the intersection of two recognised ageing hallmarks, chronic sterile inflammation and the accumulation of glycation end-products, and the company itself positions RB042 as a respiratory disease drug, not an ageing intervention. Note the company was spun out as RAGE Biotech, jointly founded with IP Group Australia, Monash University, Murdoch University, the University of Western Australia, and the Baker and Perron institutes, and now operates as Atisama Therapeutics.
ASX:CU6
Clarity Pharmaceuticals Ltd
Clinical-stage radiopharmaceutical company. Its SAR Technology platform pairs copper-64 (imaging) and copper-67 (therapy) with the same targeting molecule, so a single agent can both find and treat a tumour. Three candidates: SAR-bisPSMA (prostate cancer, lead), SAR-Bombesin (prostate and other PSMA-negative tumours) and SARTATE (neuroendocrine tumours). Relevance to the variis universe is late-life cancer detection and treatment: prostate and neuroendocrine cancers are strongly age-associated, and the company's clinical case rests on detecting recurrent disease at low PSA levels, i.e. earlier than standard-of-care imaging. Nothing in the pipeline targets ageing biology directly. Qualifies on limbs (a) and (b): ASX-listed and Australian-headquartered. Note it is pre-revenue and pre-approval; no product has regulatory approval.
SGX Catalist:1H3
Clearbridge Health Limited
Operates medical clinics and diagnostic services across Singapore, the Philippines and Hong Kong, including imaging, general health screening and vaccination. Its longevity relevance is limited and indirect: it is a clinic and screening operator, not a company developing ageing-biology interventions or aging-specific biomarker panels. The relevant exposure is preventive health screening infrastructure in Southeast Asia, which sits adjacent to the longevity clinic market. Financial condition is weak: FY2025 revenue of S$9.93m was flat year on year while net loss widened to S$12.91m, and the shares trade at S$0.001 on the SGX Catalist board with a market capitalisation of roughly S$6.4m. Include only with that caveat.
ASX:CUV
Clinuvel Pharmaceuticals
Melanocortin photomedicine (tissue resilience).
ASX:COH
Cochlear
Hearing implants (hearing loss is a modifiable dementia-risk factor).
SGX:P8A
Cordlife Group Limited
Cordlife collects, processes and cryogenically stores umbilical cord blood and cord tissue for private clients across several Asian markets, operating storage facilities rather than developing therapies. Its longevity relevance is as infrastructure for cell-based and regenerative medicine: banked haematopoietic stem cells are held against future transplant or therapeutic use. It is a storage and services business, not a therapeutics developer, and it does not run clinical programmes in ageing biology. Inclusion is on the listing limb (SGX Mainboard) and the Singapore headquarters, both confirmed. Fundamentals should be treated as unconfirmed: the company is under active Singapore Ministry of Health regulatory restriction and its FY2025 accounts carry a disclaimer of opinion.
ASX:CSL
CSL
Plasma immunoglobulins, gene therapy.
ASX:DXB
Dimerix Limited
Clinical-stage biopharmaceutical company. Its lead candidate DMX-200 (repagermanium, a chemokine receptor CCR2 antagonist given on top of an angiotensin II receptor blocker) is in the Phase 3 ACTION3 trial for focal segmental glomerulosclerosis (FSGS), a rare glomerular disease that causes scarring of the kidney's filtering units and progressive loss of kidney function toward end-stage renal disease. The trial's primary endpoint is reduction in proteinuria, with eGFR decline as a longer-term measure. A second program, DMX-700, targets orphan respiratory and renal indications and is at an earlier stage. The longevity relevance is narrow and indirect: this is rare-disease nephrology, not a geroscience or ageing-biology program. It is relevant to healthspan only insofar as declining kidney filtration is one of the core organ-decline endpoints, and DMX-200 addresses a specific genetic and idiopathic kidney disease rather than age-related renal decline in the general population. No approved products and no revenue from product sales; the company is pre-approval and dependent on trial outcomes and regional licensing partners.
Australia
Eucalyptus Health
Telehealth group founded in Sydney in 2019, operating four direct-to-consumer clinical brands: Juniper (weight management built around GLP-1 receptor agonist prescribing plus coaching), Pilot (men's health, including weight, hair loss and sexual health), Software (dermatology and skincare) and Kin (contraception, fertility and pregnancy). Its longevity relevance is distribution rather than discovery: it does not develop drugs or run biology research, but is one of the larger channels in Australia through which GLP-1 metabolic therapy is prescribed, titrated and monitored remotely, with adherence support attached. Reported 2024 revenue of A$120.9m and an after-tax loss of A$15.2m. Qualifies under limb (b), Australia-headquartered, though since June 2026 it has been a wholly owned subsidiary of NYSE-listed Hims & Hers Health rather than an independent company.
Private
Everlab
Runs a preventive health screening and diagnostics service for individual paying members. A single intake bundles whole-body MRI, CT coronary angiography, DEXA body composition and bone density, VO2 max and isometric strength testing, ECG, continuous glucose monitoring and blood panels covering more than 100 biomarkers across cardiovascular, metabolic, hormonal, inflammatory, toxicological and performance domains. Results are pulled into one record alongside clinician review, specialist referral, prescriptions and wearable data, with the stated aim of catching disease risk earlier than standard primary care. Pricing is tiered, from A$499 for a blood biomarker package to A$2,999 a year for the full programme. The longevity relevance is screening and early detection, not any therapeutic or ageing-modifying intervention: the company sells testing and care coordination, and no published outcome data establishing that its screening extends life or reduces mortality was found in the sources reviewed.
ASX:GSS
Genetic Signatures Limited
Molecular diagnostics company built on its proprietary 3base sample-chemistry platform, which converts non-methylated cytosines before amplification to reduce sequence complexity and allow highly multiplexed real-time PCR. It sells EasyScreen kits and the GS1 automated workflow to clinical laboratories for gastrointestinal (bacterial, viral, parasitic), respiratory, and vaccine-preventable pathogen detection, with customers in Australia, the UK, and the US. Longevity relevance is peripheral and indirect: the exposure is infectious disease testing infrastructure, not ageing biology, biological age measurement, or any geroscience intervention. It belongs in the universe on the diagnostics limb and on ASX listing, not on scientific proximity to healthspan. Nothing in its product line targets ageing mechanisms.
Private
harrison.ai
Builds clinical AI software that reads medical images and flags findings for clinicians. Its radiology products cover chest X-ray and non-contrast head CT (the company and press reporting cite up to 124 findings on chest X-ray and up to 130 on non-contrast head CT), with a separate pathology line aimed at slide review and workflow. The longevity relevance is earlier detection of disease at scale rather than any intervention on ageing biology: the software is deployed in over 1,000 healthcare facilities and is sold into radiology and pathology providers, including shareholder-linked networks Sonic Healthcare and I-MED Radiology. It does not develop drugs or therapeutics.
Private
Hummingbird Bioscience
A Singapore-headquartered antibody drug developer. It designs monoclonal antibodies and antibody-drug conjugates against targets it selects computationally, then develops them for cancer and autoimmune disease. Current clinical assets are HMBD-001 (anti-HER3 antibody) and HMBD-501 (a HER3-directed antibody-drug conjugate, dosed in its first Phase I patient in January 2026). It has also out-licensed programmes: HMBD-002 (anti-VISTA) to Percheron Therapeutics in June 2025, and an undisclosed-target antibody to Immunome in January 2025. Its longevity relevance is indirect rather than direct. It does not work on ageing biology, senescence, metabolic ageing or healthspan endpoints. The connection is that cancer is a leading age-related cause of death, so better-targeted oncology therapeutics extend life in an older population. Read as an oncology biotech that sits in the SG/AU universe on headquarters grounds, not as a geroscience company.
SGX:Q0F
IHH Healthcare Berhad
Operates a private hospital network of 89 hospitals across 10 countries (Malaysia, Singapore, Turkiye, India, China, Hong Kong, Brunei, Bulgaria, North Macedonia, Netherlands, Serbia), including the Mount Elizabeth, Gleneagles and Parkway brands in Singapore. Its longevity relevance is delivery-side rather than therapeutic: it is the largest listed vehicle for age-related clinical care in Asia, with revenue concentrated in cardiology, oncology and orthopaedics, the specialties that scale with an ageing population. It also runs an SGD 80 million innovation fund backing startups in cancer diagnostics, digital health, proton therapy, mental health and sleep disorders. It does not develop geroprotective drugs or biological-age interventions. Inclusion is confirmed under limb (a): SGX secondary line Q0F verified on a live SGX healthcare sector listing.
ASX:IMM
Immutep Limited
Immutep develops immunotherapies built around LAG-3, an immune checkpoint protein that regulates T-cell activity. Its portfolio runs in two directions from the same biology: agonist-style candidates (led by eftilagimod alfa, a soluble LAG-3 protein) intended to stimulate antigen-presenting cells and T-cells against tumours, and antagonist candidates intended to damp down T-cell activity in autoimmune disease. That two-sided position on T-cell regulation is what makes it relevant to the immune-ageing (immunosenescence) axis rather than to a single tumour type. It is not a geroscience company and does not run ageing-endpoint trials; the longevity link is mechanistic, via immune regulation, not by stated intent. Inclusion is on both limbs of the rule: ASX-listed and Sydney-headquartered. The honest negative: its most advanced oncology programme failed a Phase III interim futility analysis in March 2026, so the near-term clinical case rests on the remaining earlier-stage assets.
ASX:MSB / NASDAQ:MESO
Mesoblast
First FDA-approved MSC product (Ryoncil).
ASX:MX1
Micro-X Limited
Micro-X designs and manufactures X-ray and CT imaging hardware built on carbon-nanotube ("cold cathode") emitters, which let the tube be far smaller and lighter than conventional thermionic X-ray tubes. Its commercial product is the Rover / Rover Plus mobile digital radiography unit, a portable X-ray system used where patients cannot easily be moved to a fixed radiology suite: emergency departments, intensive care, operating theatres, remote and field settings. In development is an ultra-lightweight head CT scanner intended to be carried in an ambulance so that stroke can be imaged and triaged before the patient reaches hospital, plus earlier-stage portable full-body CT and lung CT work. The longevity relevance is infrastructural rather than therapeutic: it addresses point-of-care imaging for immobile and frail patients and time-to-diagnosis in stroke, a condition whose incidence rises sharply with age. It is not a geroscience or ageing-biology company, and the Micro-X site does not itself market Rover as an aged-care product, so the aged-care framing should be treated as an inference about the use case rather than a company claim. Micro-X also sells non-medical security screening products (baggage and checkpoint scanners), so medical imaging is only part of the revenue base.
HKEX:2629
Mirxes Holding Company Limited
Develops and sells blood-based microRNA diagnostic tests for early cancer detection. Its lead product, GASTROClear, is a 12-biomarker blood panel for gastric cancer screening; it also markets LUNGClear for lung cancer and Fortitude infectious-disease assays. The longevity relevance is early detection rather than any ageing-biology intervention: catching cancer at a screenable, asymptomatic stage in high-risk adults. Qualifies for the variis universe on the headquarters limb (Singapore), not the exchange limb, as it is listed on HKEX rather than SGX or ASX.
Private
Nuevocor Pte Ltd
Clinical-stage genetic medicines company developing gene therapies for inherited cardiomyopathies, using a mechanobiology approach that targets the mechanical stress signalling inside failing heart muscle cells rather than correcting the mutated gene directly. Lead asset NVC-001 is an AAV-delivered therapy for LMNA-related dilated cardiomyopathy, an aggressive genetic heart-muscle disease with no targeted treatment. Longevity relevance is disease-specific rather than general: it aims to halt progression of a condition that causes heart failure and early death in carriers, not to modify ageing biology broadly. Both Singapore HQ and incorporation as a Pte Ltd confirmed on the company site, so it meets limb (b) of the inclusion rule.
Private
Nutromics
Nutromics builds a wearable "lab-on-a-patch" that uses DNA-aptamer biosensors on a microneedle array to measure molecules in interstitial fluid continuously, rather than at single points via blood draws. The lead indication is therapeutic drug monitoring of vancomycin in intensive care sepsis patients, an antibiotic with a narrow therapeutic window that is hard to dose correctly. The company has also shown simultaneous real-time measurement of two antibiotics (vancomycin and tobramycin) on one device in animal models, and is working on a sepsis management patch. The longevity relevance is infrastructural rather than an intervention: it is a platform for continuous biomarker tracking that could extend beyond drugs to other dynamic analytes, shifting diagnostics from episodic lab tests to trend data. No product has regulatory approval anywhere; the company states FDA clearance for vancomycin monitoring is targeted from 2028, so nothing is in clinical use today.
ASX:OCC
Orthocell Limited
Orthocell makes collagen-based implantable devices and autologous cell therapies for repairing tissue that degrades or fails to heal with age: peripheral nerve, tendon, bone and cartilage. Three commercial products: Remplir, a collagen wrap used in peripheral nerve repair surgery; Striate+, a collagen membrane for dental bone regeneration; and OrthoACI, an autologous chondrocyte implantation therapy for cartilage defects. Remplir is the commercial driver, cleared for sale in 45 US states with distribution also in Canada and Australia. The longevity relevance is demand-side rather than mechanistic: this is surgical tissue repair for an older population, not an intervention targeting biological ageing itself. Revenue is real but small (A$13.2m in FY2026), and US unit volumes remain modest (119 devices in the June 2026 quarter).
SGX Catalist:5WA
OUE Healthcare Limited
Qualifies on both limbs: listed on SGX Catalist under 5WA and headquartered in Singapore. It is an investment holding company that owns, operates and invests in healthcare businesses across Singapore, China, Myanmar, Indonesia and Japan, running hospitals and specialist clinics, supplying medical equipment and pharmaceuticals, and holding healthcare property and development assets. Parent is OUE Limited. Its longevity relevance is indirect and infrastructural rather than biological: it is a private healthcare services operator, not a developer of ageing-targeted therapeutics or diagnostics. The nearest direct link is its stated push into specialised care and an integrative medicine offering combining traditional and Western treatment, which sits adjacent to preventive and wellness-oriented care. There is no disclosed geroscience, senolytic, biological-age testing or longevity-clinic programme. Treat it as a delivery-channel holding in the SG universe, not an intervention developer. Financial scale was not verified: the shares traded around SGD 0.03 on 17 July 2026 per StockAnalysis, but no market capitalisation figure was retrieved, so that field is left null rather than estimated.
ASX:PME
Pro Medicus
Imaging/radiology AI (early detection).
SGX:BSL
Raffles Medical Group Ltd
An integrated private healthcare provider, not a longevity biotech. Founded 1976 and headquartered at Raffles Hospital, 585 North Bridge Road, Singapore, it runs family medicine clinics, specialist centres, hospitals, dental and Chinese medicine practices, insurance and healthcare products across Singapore, China, Vietnam, Cambodia and Japan. The longevity-relevant part is a preventive and chronic-care line rather than the group as a whole: health screening packages, an executive medical centre, statutory health checks, corporate health programmes covering more than 7,000 corporate clients, and chronic disease management delivered through its primary care network. That makes it the closest SGX-listed proxy for a clinical healthspan business, but the revenue base is conventional hospital and clinic services, and the company makes no ageing-biology or lifespan-extension claim. Treat it as delivery infrastructure for preventive medicine, not as an intervention developer.
ASX:REG
Regis Healthcare Limited
Operates aged care and later-life accommodation services across Australia: residential aged care homes, home care packages delivered in people's own homes, short-term and respite care, and retirement living. Facilities span Queensland, Victoria, New South Wales, Western Australia, South Australia, Tasmania and the Northern Territory. Its relevance to longevity is economic and infrastructural rather than biomedical: it does not develop drugs, diagnostics or interventions that alter ageing biology. It is a listed proxy for how Australia funds and delivers care in the final decades of life, with revenue tied directly to the Commonwealth's AN-ACC funding model (about A$295 per resident per day) and to resident co-contributions. Inclusion rule is met on both limbs: ASX-listed and Australian headquartered.
NYSE:RMD / ASX:RMD (CDIs)
ResMed
Sleep/respiratory; GLP-1 screening beneficiary.
SGX Catalist:9G2
Singapore Institute of Advanced Medicine Holdings Ltd
Operates a single-site Singapore medical centre built around advanced imaging and radiation oncology. Two reported segments: medical diagnostics and treatments (cancer diagnostics, nuclear medicine, general health screening, aesthetic services) and radiation therapy and medical oncology (proton beam therapy, photon radiation therapy, medical oncology). Its stated clinical focus spans cancer, neurodegenerative and cardiovascular disease detection. The longevity-relevant part is the diagnostics and imaging arm: high-resolution and nuclear-medicine imaging plus paid health screening is early-detection infrastructure, the same category as preventive screening plays. The proton-beam oncology business is treatment for existing disease, not a longevity intervention, and is the larger capital commitment. There is no geroscience, biomarker-of-ageing, or therapeutic-development activity here. It is a small, loss-making clinical operator: FY2025 revenue SGD 15.71m, down 5.6% year on year, with a net loss of SGD 27.05m, and a market capitalisation under SGD 50m. Note the corporate site www.sam.com.sg did not resolve on repeated attempts, so the business description above rests on exchange-data aggregators rather than company disclosure.
ASX:SPL
Starpharma
Dendrimer drug-delivery.
Singapore
TalkMed Group Limited
Runs private medical oncology and palliative care practices in Singapore, delivered mainly through Parkway Cancer Centre, with sub-specialty coverage of breast, head and neck, gastro-intestinal, uro-gynaecological and haematological cancers, plus ancillary health services, medical technology services and some overseas operations. The longevity relevance is indirect and delivery-side rather than mechanistic: it is late-stage disease treatment and supportive care, not an ageing-biology intervention. Inclusion rule is met on both limbs (Singapore-headquartered, and formerly SGX Mainboard listed). It is no longer investable on public markets: the shares were delisted with effect from 15 September 2025 after a scheme-of-arrangement privatisation by TW Troy Limited. The former SGX counter code was 5G3; the ticker field is left null because that security no longer trades. The claim that the acquiring vehicle sits under pan-Asian oncology group Tamarind Health was not confirmed by the sources retrieved here, so it is not asserted.
ASX:TLX / NASDAQ:TLX
Telix Pharmaceuticals
Radiopharmaceutical theranostics (cancers of ageing).
SGX:A50
Thomson Medical Group Limited
Operator of private hospitals and clinics, with the group's distinctive concentration in women's health, fertility and maternity care. Its Singapore assets include Thomson Medical Centre and a network of women's clinics, fertility/IVF services and paediatric centres; it also operates in Malaysia (Thomson Hospital Kota Damansara) and Vietnam (FV Hospital, acquired 2023). The longevity-relevant limb is reproductive ageing: IVF and fertility treatment address declining ovarian reserve and age-related fertility loss in an ageing, low-birth-rate region. This is clinical service delivery, not geroscience research; the group does not develop ageing-directed therapeutics or biomarkers. Inclusion is on listing and HQ grounds (SGX-listed, Singapore-headquartered), with fertility as the thematic tie rather than any lifespan or healthspan intervention.
Private
Vaxxas
Vaxxas is a private Brisbane biotechnology company developing a high-density microarray patch (HD-MAP), a needle-free vaccine delivery device derived from University of Queensland research. The patch carries thousands of vaccine-coated microprojections that are pressed into the skin for a few seconds, depositing vaccine into the immune-cell-rich layer immediately below the surface rather than into muscle. The claimed advantages are dose-sparing, reduced cold-chain dependence, and the possibility of self-administration at home. It meets the inclusion rule on limb (b), Australian headquarters, and the company confirms it is private (Vaxxas Pty Ltd, Series D equity plus debt, August 2025). The longevity link is indirect and should be read that way: Vaxxas is a delivery platform, not a therapeutic, and makes no ageing-biology claim. The relevance to a longevity universe is preventive-health and immunosenescence adjacency, since intradermal delivery is the route most often studied for improving vaccine response in older adults whose immune systems respond poorly to intramuscular injection, and since a lower-cost, cold-chain-light delivery format bears on population-scale preventive coverage. Vaxxas has not published a specific older-adult immunogenicity programme that was verifiable from the sources opened here. Treat it as peripheral to the core longevity thesis.